Tatsuo Yanagawa
Magnesium (Mg) deficiency is linked to diabetes and cardiovascular (CV) events. Treatment with the sodiumglucose cotransporter 2 (SGLT2) inhibitor was associated with a suppressed occurrence of CV events in patients with type 2 diabetes. We recently suggested that the increase of the serum Mg level associated with SGLT2 inhibitor treatment could explain, at least in part, the reduction of the CV events. Recently SGLT2 inhibitors have also been reported to exert a renoprotective effect and various hypotheses have been proposed regarding the mechanism. Now we would like to propose another possible mechanism, namely, the role of Mg.
